NCT02867007View on ClinicalTrials.gov

KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

December 15, 2019

Study Completion Date

December 15, 2019

Conditions
Solid TumorCancerCarcinoma
Interventions
DRUG

KHK2455

oral dosing

DRUG

Mogamulizumab

i.v. administration

Trial Locations (4)

33612

Tampa

77030

Houston

87106

Albuquerque

94800

Paris

Sponsors

Lead Sponsor

Kyowa Kirin, Inc.
All Listed Sponsors
lead

Kyowa Kirin, Inc.

INDUSTRY